Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

Share-based compensation

9 Months Ended

Sep. 30, 2022

Note 12 — Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended			Nine months ended
		September 30,			September 30,
	2022		2021		2022		2021
Research and development	$	447	$	2,177	$	5,003	$	7,064
General and administrative		3,216		2,842		9,291		8,738
	$	3,663	$	5,019	$	14,294	$	15,802

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended			Nine months ended
		September 30,			September 30,
	2022		2021		2022		2021
Number of options over ordinary shares granted		5,996,581		4,170,230		30,608,533		19,891,334
Weighted average fair value of ordinary shares options	$	0.21	$	0.51	$	0.37	$	0.70
Number of additional options with a nominal exercise price granted		1,866,216		1,348,920		22,916,376		16,008,168
Weighted average fair value of options with a nominal exercise price	$	0.28	$	0.70	$	0.53	$	0.98